Novo Nordisk A/S Sued for Securities Law Violations - Contact The Gross Law Firm Before March 25, 2025 to Discuss Your Rights - NVO

Core Viewpoint - Novo Nordisk A/S faced a significant drop in stock price following the announcement of disappointing results from their "REDEFINE 1" trial, which investigated the efficacy of CagriSema for weight loss [1][2]. Group 1: Trial Results - The "REDEFINE 1" trial showed that patients treated with CagriSema experienced a weight loss of 22.7% after 68 weeks, which was below the company's target expectation of at least 25% [1]. - Only 57.3% of patients in the trial were on the highest dosage of CagriSema, as participants were allowed to modify their own dosage during the trial [1]. Group 2: Stock Price Impact - Following the press release regarding the trial results, Novo's stock price fell by $18.44 per share, closing at $85.00 per share [1]. Group 3: Class Action Information - Shareholders who purchased shares of Novo Nordisk during the class period from November 2, 2022, to December 19, 2024, are encouraged to register for a class action lawsuit [2]. - The deadline for shareholders to seek lead plaintiff status is March 25, 2025, and there is no cost or obligation to participate in the case [2].